- Conditions
- Sickle Cell Disease
- Interventions
- Alemtuzumab, Fludarabine, Melphalan, Cyclosporine, Tacrolimus, Methotrexate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 13 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more
Location Directory
Clinical trials in Phoenix, Arizona
This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8148
Shown on this page
12
Current sort
Recently updated
Location scope
Phoenix, AZ
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 721–732 of 8,148 matching trials in Phoenix, AZ.
Live ClinicalTrials.gov results.
Institutions in Phoenix
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
- Interventions
- ctDNA-Guided Treatment Strategy
- Device
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2037
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
- Conditions
- Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
- Interventions
- LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo, LY4065967 ISA
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 52 more
- Conditions
- Burn, Trauma Wound, Full Thickness Wounds, Surgical Wound
- Interventions
- Cohealyx
- Device
- Lead sponsor
- Avita Medical
- Industry
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
- Conditions
- Lung Transplant Rejection
- Interventions
- Belumosudil, Azithromycin, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Bipolar I or II Disorder
- Interventions
- ABBV-932
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Anaheim, California • Colton, California + 41 more
- Conditions
- Relapsing Multiple Sclerosis, Multiple Sclerosis
- Interventions
- No Intervention
- Other
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 98 more
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 78
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
- Interventions
- Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 29 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
- Conditions
- Surgical Wound, Trauma Wound, Autografts, Partial-thickness Burn, Partial Thickness Wounds
- Interventions
- PermeaDerm Biosynthetic Wound Matrix, Frozen Human Cadaveric Allograft (FHCA)
- Device
- Lead sponsor
- Avita Medical
- Industry
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more